The UNC Breast Cancer SPORE Tissue Procurement & Pathology Core (TPP) Facility is a multifunctional facility, comprised of multiple components including Tissue Procurement and Translational Pathology. This Core provides centralized, quality controlled, quality assured procurement, processing, analysis, storage and distribution of normal and malignant breast tissue, blood specimens and other human specimens in support of basic science, translational, genomic, population and clinical trial cancer research. In addition to tissue and blood procurement services, the facility performs extraction of high quality DNA from whole blood, peripheral blood mononuclear cells, buccal smears and mouth rinses and immortalization of breast cancer patient lymphocytes. Importantly this group provides functional access to many other scientific and administrative groups such as Immunogenetics and Analysis and the Office of Clinical Translational Research. The Lineberger Data Warehouse (Core B), an Oracle-based, customized user-friendly database, operating on an honest broker model to protect identity and confidentiality, provides the infrastructure to monitor and survey each specimen and associated information. This provides a coordinated system of quality control, sample tracking and distribution of specimens to appropriate investigators. Breast cancer-specific efforts that have and will support SPORE aims include centralized tissue and specimen banking, receipt and processing of breast-related human specimens including: freshly procured, snap-frozen and formalin fixed paraffin embedded (FFPE) block specimens, preparation of tissue microarrays (TMAs), cell microarrays, morphological evaluation and morphology-based assays (immunohistochemistry, immunofluorescence, in-situ hybridization, and fluorescence in-situ hybridization), assay development & training, and digital imaging and image analysis for spatial quantification of molecular analytes in intact specimens. Project # 1, CBCS, has used the core for over two decades. Projects #2, #3, and #4 will specifically use the cores for samples from clinical trials (Projects #3 and #4) and to obtain fresh tissue to flow sort cells for assays (Project #2) and to prepare primary cultured cells from individual patients (Projects #2 and #4).

Public Health Relevance

The UNC Breast SPORE has heavily integrated tissue and blood-based studies that require a high performance Biospecimens/Pathology Core. These include high-volume analyses on FFPE tissues for population-based studies (Project 1), high complex analyses on fixed and frozen tissue from clinical trials (Project #3), and frozen tissue procurement and processing for lab-based translational studies (Projects #2 and #4).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-25
Application #
9768357
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
25
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330

Showing the most recent 10 out of 598 publications